Valsartan D9
(Synonyms: 缬沙坦 D9; CGP 48933-d9) 目录号 : GC37884An internal standard for the quantification of valsartan
Cas No.:1089736-73-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats: Rats are randomly divided into two groups: (i) valsartan-treated group that is given intravenously 3 mg/kg/day valsartan in 0.5 mL normal saline via the vein daily for 1 week; (ii) hydralazine-treated group receiving 0.2 mg/kg/day hydralazine injection in saline; and (iii) control group that receives saline injection in the same way (n=15 for each group)[4]. Mice: Valsartan is dissolved in water containing 0.5% methylcellulose solution. Valsartan (5-40 mg/kg/d) is administered by oral (p.o.) route in a volume of 10 mL/kg body weight using the gavage technique. Potential alteration in blood pressure in response to chronic treatment with valsartan is assessed with a commercial blood pressure analysis systemdesigned. The mice are trained for at least 2 consecutive days to adapt to the apparatus before the study is initiated. To record the blood pressure, the mice are placed on a heated pad (35°C) and measured with a programmable tail-cuff sphygmomanometer in steady state. The average of 10 readings from each mouse is recorded[5]. |
References: [1]. Shan H, et al. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014 Jun;18(6):1071-80. |
Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).1 It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro.2 In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.3 Formulations containing valsartan have been used in the treatment of hypertension and heart failure.4,2,5
1.Burnier, M.Angiotensin II type 1 receptor blockersCirculation103(6)904-912(2001) 2.Munger, M.A.Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directionsPT36(1)22-40(2011) 3.Suematsu, Y., Miura, S., Goto, M., et al.LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic miceEur. J. Heart Fail.18(4)386-393(2016) 4.Irons, B.K., Tsikouris, J.P., and Thomas, A.A.The use of angiostensin receptor blockers in the treatment of chronic hear failureJ. Cardiovasc. Pharmacol.44(6)718-724(2004) 5.Schiffrin, E.L.Beyond blood pressure: The endothelium and atherosclerosis progressionAm. J. Hypertens.15(10 Pt 2)115S-122S(2002)
Cas No. | 1089736-73-1 | SDF | |
别名 | 缬沙坦 D9; CGP 48933-d9 | ||
Canonical SMILES | CC(C)[C@@H](C(O)=O)N(C(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)CC(C=C1)=CC=C1C2=CC=CC=C2C3=NN=NN3 | ||
分子式 | C24H20D9N5O3 | 分子量 | 444.57 |
溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2494 mL | 11.2468 mL | 22.4936 mL |
5 mM | 0.4499 mL | 2.2494 mL | 4.4987 mL |
10 mM | 0.2249 mL | 1.1247 mL | 2.2494 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。